One week on Ozempic: what results are actually realistic?

What did @jess.mcgirr actually say?

The short version: she baited viewers with a fake 'one week on Ozempic results' hook, then revealed she was never on it, and used the pivot to push two main claims. First, that you can buy semaglutide online in America with next-day delivery. Second, that 'Ozempic is so bad for you' and that pharmaceutical companies want to keep patients 'sicker and sicker' as lifelong customers paying $500 a month.

She also framed working out four times a week at a gym as the morally superior alternative. The video is less a health update and more a conspiratorial editorial dressed up as a results video. That framing matters when 69,900 people see it.

Does the science back this up?

On the 'bad for you' claim: not in any blanket sense. The evidence base for semaglutide is actually one of the more robust in recent obesity medicine. The SUSTAIN and STEP trial programs showed meaningful reductions in body weight, blood glucose, and cardiovascular events in high-risk populations.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found participants on semaglutide 2.4mg lost an average of 14.9% of body weight versus 2.4% on placebo over 68 weeks. The SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major adverse cardiovascular events among people with obesity but without diabetes. These are not small studies run by fringe researchers. They are large, randomized, peer-reviewed trials.

That does not mean the drugs carry zero risk. Gastrointestinal side effects are common. Rare cases of pancreatitis and gallbladder disease have been documented. Muscle mass loss alongside fat loss is a real concern flagged in current literature. But 'Ozempic is bad for you' as a universal statement is not supported by evidence.

What did they get wrong (or right)?

She got one thing right, and it matters: the accessibility point is legitimate. Compounded semaglutide has been widely available through telehealth platforms during the FDA shortage period, with very limited in-person oversight. That is a genuine regulatory gap worth discussing, and the FDA has flagged concerns about compounded GLP-1 products precisely because quality and dosing consistency are not guaranteed the way they are with FDA-approved formulations.

But the 'bad for you' claim is where she goes off the rails. It is a vague, evidence-free assertion aimed at a large audience. The people most likely to be watching a 'one week Ozempic results' video are people actively considering or already using the medication. Telling them it will make them 'sicker and sicker' without any clinical basis is not skepticism. It is misinformation with a wellness aesthetic.

The 'lifelong customer' framing also oversimplifies. Weight regain after stopping semaglutide is well-documented (Wilding et al., 2022, Diabetes, Obesity and Metabolism), and that is a legitimate conversation about drug dependency versus chronic disease management. But implying malicious intent without evidence is a different thing entirely.

What should you actually know?

GLP-1 receptor agonists are not a perfect drug class, but they are not a scam either. The clinical picture is more complicated than either 'miracle shot' influencers or anti-pharma skeptics suggest.

Side effects are real and should be taken seriously. Nausea, vomiting, and GI distress affect a significant portion of users. Rare but serious risks including pancreatitis and thyroid C-cell tumors in rodent studies (with human risk still under evaluation) appear in the prescribing information for a reason. Muscle mass loss is a legitimate concern, particularly without adequate protein intake and resistance training.

On cost: the $500 a month figure she cites is roughly accurate for out-of-pocket brand-name pricing without insurance. That is a real access and equity issue. Compounded alternatives exist but carry their own risks around standardization and oversight.

The actual takeaway is this: if you are considering a GLP-1 medication, the decision should happen with a licensed clinician who knows your full health history, not based on a TikTok video from someone who was never on the drug in the first place.